APA (7th ed.) Citation

G, G., A, R., C, G., E, G., F, V., L, D. T., . . . A, P. (2026). Differential musculoskeletal outcome reporting in patients receiving bempedoic acid or atorvastatin: A disproportionality analysis using the EudraVigilance database. Frontiers in pharmacology, 16, 1736657. https://doi.org/10.3389/fphar.2025.1736657

Chicago Style (17th ed.) Citation

G, Gazzaniga, et al. "Differential Musculoskeletal Outcome Reporting in Patients Receiving Bempedoic Acid or Atorvastatin: A Disproportionality Analysis Using the EudraVigilance Database." Frontiers in Pharmacology 16 (2026): 1736657. https://doi.org/10.3389/fphar.2025.1736657.

MLA (9th ed.) Citation

G, Gazzaniga, et al. "Differential Musculoskeletal Outcome Reporting in Patients Receiving Bempedoic Acid or Atorvastatin: A Disproportionality Analysis Using the EudraVigilance Database." Frontiers in Pharmacology, vol. 16, 2026, p. 1736657, https://doi.org/10.3389/fphar.2025.1736657.